This Article Full Text Full Text (PDF) Supplementary Data All Versions of this Article: 0008-5472.CAN-08-3365v1 69/5/1702    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liu, T. Articles by Marshall, G. M. Search for Related Content PubMed PubMed Citation Articles by Liu, T. Articles by Marshall, G. M. Related Collections Cellular Pathobiology Cellular Pathobiology: Cancer Genes and Genomics

The Critical Role of the Class III Histone Deacetylase SIRT1 in Cancer

¹ Children's Cancer Institute Australia for Medical Research and ² Centre for Children's Cancer and Blood Disorders, Sydney Children's Hospital, Randwick, Sydney, New South Wales, Australia

Requests for reprints: Glenn M. Marshall, Centre for Children's Cancer and Blood Disorders, Sydney Children's Hospital, High Street, Randwick, Sydney, NSW 2031, Australia. Phone: 61-2-93821721; Fax: 61-2-93821789; E-mail: g.marshall{at}unsw.edu.au.

Key Words: SIRT1 • deacetylation • methylation • tumorigenesis • experimental therapy

Gene expression and deacetylase activity of the class III histone deacetylase SIRT1 are up-regulated in cancer cells due to oncogene overexpression or loss of function of tumor suppressor genes. SIRT1 induces histone deacetylation and methylation, promoter CpG island methylation, transcriptional repression, and deacetylation of tumor suppressor proteins. SIRT1 may play a critical role in tumor initiation, progression, and drug resistance by blocking senescence and apoptosis, and promoting cell growth and angiogenesis. SIRT1 inhibitors have shown promising anticancer effects in animal models of cancer. Further screening for more potent SIRT1 inhibitors may lead to compounds suitable for clinical trials in patients. [Cancer Res 2009;69(5):1702–5]

This article has been cited by other articles:

				N. VALERI, C. M. CROCE, and M. FABBRI Pathogenetic and Clinical Relevance of MicroRNAs in Colorectal Cancer Cancer Genomics Proteomics, July 1, 2009; 6(4): 195 - 204. [Abstract] [Full Text] [PDF]

				D. S. Schrump Cytotoxicity Mediated by Histone Deacetylase Inhibitors in Cancer Cells: Mechanisms and Potential Clinical Implications Clin. Cancer Res., June 15, 2009; 15(12): 3947 - 3957. [Abstract] [Full Text] [PDF]